Www.medicinebau.com

Patients should have no evidence of residual cancer on repeat TUR, and should not have any evidence of associated CIS or prostatic urethral involvement. The role of definitive TUR was illustrated by a retrospective series of 432 patients with muscle invasive bladder cancer who had been referred for definitive management [65]. ................
................